Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Fundamental Analysis

NASDAQ:CADL - Nasdaq - US1374041093 - Common Stock

7.04  +0.43 (+6.51%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CADL. CADL was compared to 572 industry peers in the Biotechnology industry. Both the profitability and financial health of CADL have multiple concerns. CADL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CADL had negative earnings in the past year.
CADL had a negative operating cash flow in the past year.
In the past 5 years CADL always reported negative net income.
In the past 5 years CADL always reported negative operating cash flow.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -92.10%, CADL is doing worse than 72.74% of the companies in the same industry.
CADL's Return On Equity of -297.72% is on the low side compared to the rest of the industry. CADL is outperformed by 74.87% of its industry peers.
Industry RankSector Rank
ROA -92.1%
ROE -297.72%
ROIC N/A
ROA(3y)-52.25%
ROA(5y)-44.18%
ROE(3y)-131.12%
ROE(5y)-96.56%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CADL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

2

2. Health

2.1 Basic Checks

CADL does not have a ROIC to compare to the WACC, probably because it is not profitable.
CADL has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, CADL has a worse debt to assets ratio.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

CADL has an Altman-Z score of -1.17. This is a bad value and indicates that CADL is not financially healthy and even has some risk of bankruptcy.
CADL's Altman-Z score of -1.17 is in line compared to the rest of the industry. CADL outperforms 57.70% of its industry peers.
CADL has a Debt/Equity ratio of 0.97. This is a neutral value indicating CADL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.97, CADL is not doing good in the industry: 78.94% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF N/A
Altman-Z -1.17
ROIC/WACCN/A
WACC11.2%
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.59 indicates that CADL has no problem at all paying its short term obligations.
CADL's Current ratio of 2.59 is on the low side compared to the rest of the industry. CADL is outperformed by 70.44% of its industry peers.
A Quick Ratio of 2.59 indicates that CADL has no problem at all paying its short term obligations.
CADL's Quick ratio of 2.59 is on the low side compared to the rest of the industry. CADL is outperformed by 69.38% of its industry peers.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.59
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CADL have decreased strongly by -21.43% in the last year.
The Revenue for CADL has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, CADL will show a very strong growth in Earnings Per Share. The EPS will grow by 45.34% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-23.75%
EPS Next 2Y45.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CADL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CADL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CADL's earnings are expected to grow with 45.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.34%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CADL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANDEL THERAPEUTICS INC

NASDAQ:CADL (1/22/2025, 10:30:06 AM)

7.04

+0.43 (+6.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2024-03-28/bmo
Earnings (Next)N/A N/A
Inst Owners20.18%
Inst Owner Change0.6%
Ins Owners29.02%
Ins Owner Change-30.78%
Market Cap296.60M
Analysts82.86
Price Target19.38 (175.28%)
Short Float %9.25%
Short Ratio0.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-96.4%
Min EPS beat(2)-132.84%
Max EPS beat(2)-59.96%
EPS beat(4)1
Avg EPS beat(4)-49.23%
Min EPS beat(4)-132.84%
Max EPS beat(4)7.56%
EPS beat(8)4
Avg EPS beat(8)-14.45%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)72.73%
PT rev (3m)72.73%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-81.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 23.27
P/tB 23.27
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-1.68
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS0
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -92.1%
ROE -297.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.25%
ROA(5y)-44.18%
ROE(3y)-131.12%
ROE(5y)-96.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.59
Quick Ratio 2.59
Altman-Z -1.17
F-Score2
WACC11.2%
ROIC/WACCN/A
Cap/Depr(3y)338.09%
Cap/Depr(5y)611.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-111.11%
EPS Next Y-23.75%
EPS Next 2Y45.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.85%
EBIT Next 3Y35.99%
EBIT Next 5Y55.1%
FCF growth 1Y-6.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.99%
OCF growth 3YN/A
OCF growth 5YN/A